Tetraphenylphosphonium

Tetraphenylphosphonium

SCHEMBL585136

[F-].c1ccc([P+](c2ccccc2)(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.47
ALDH1A1 P00352 5/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MGLL Q99685 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TSHR P16473 5/20 0.35
DPP4 P27487 2/20 0.35
F2 P00734 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA9 Q16790 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
MAPK1 P28482 1/20 0.33
CA12 O43570 1/20 0.33
GLA P06280 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetraphenylphosphonium SCHEMBL7906432 0.96 HIF1A (0.45) HIF1AALDH1A1MAPTHPGDSMN1; SMN2
Tetraphenylphosphonium SCHEMBL3300848 0.96 HIF1A (0.45) HIF1AALDH1A1MAPTHPGDSMN1; SMN2
Tetraphenylphosphonium SCHEMBL3304548 0.96 HIF1A (0.45) HIF1AALDH1A1MAPTHPGDSMN1; SMN2
Tetraphenylphosphonium SCHEMBL29362652 0.96 HIF1A (0.50) HIF1AALDH1A1MAPTHPGDSMN1; SMN2
Tetraphenylphosphonium SCHEMBL9547828 0.93 HIF1A (0.43) HIF1AALDH1A1MAPTHPGDSMN1; SMN2
Tetraphenylphosphonium SCHEMBL108817 0.92 HIF1A (0.47) HIF1AALDH1A1MAPTHPGDSMN1; SMN2
Tetraphenylphosphonium SCHEMBL19921940 0.92 HIF1A (0.47) HIF1AALDH1A1MAPTHPGDSMN1; SMN2
Tetraphenylphosphonium SCHEMBL30168547 0.92 HIF1A (0.47) HIF1AALDH1A1MAPTHPGDSMN1; SMN2
Tetraphenylphosphonium SCHEMBL30623276 0.92 HIF1A (0.47) HIF1AALDH1A1MAPTHPGDSMN1; SMN2
Tetraphenylphosphonium SCHEMBL9638111 0.92 HIF1A (0.47) HIF1AALDH1A1MAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 431 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12173150-B2 Polyester carbonates from cycloaliphatic diacids and aliphatic diols, and process for preparing same COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) 2024-12-24 US claimed
US-11945909-B2 Process for preparing polycarbonates using a catalyst system having a quarternary nitrogen compond and a quarternary phosphorous compound EPC Engineering & Technologies GmbH (DE) 2024-04-02 US claimed
EP-3526274-B1 CATALYST SYSTEM EPC ENGINEERING & TECH GMBH (DE) 2022-08-03 EP claimed
US-20220073737-A1 POLYESTER CARBONATES FROM CYCLOALIPHATIC DIACIDS AND ALIPHATIC DIOLS, AND PROCESS FOR PREPARING SAME COVESTRO DEUTSCHLAND AG (DE) 2022-03-10 US claimed
CN-113788784-A Preparation method of 2-fluoro-3-trifluoromethylpyridine 山东省农药科学研究院 2021-12-14 CN claimed
EP-3898764-A1 POLYESTER CARBONATES FROM CYCLOALIPHATIC DIACIDS AND ALIPHATIC DIOLS, AND PROCESS FOR PREPARING SAME Covestro Intellectual Property GmbH & Co. KG (DE) 2021-10-27 EP claimed
CN-113166384-A Polyester carbonates made from cycloaliphatic diacids and aliphatic diols and methods for making the same 科思创知识产权两合公司 2021-07-23 CN claimed
US-11038171-B2 Active material including composite fluoride for fluoride ion secondary battery, and fluoride ion secondary battery using the same PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) 2021-06-15 US claimed
WO-2020126806-A1 POLYESTER CARBONATES FROM CYCLOALIPHATIC DIACIDS AND ALIPHATIC DIOLS, AND PROCESS FOR PREPARING SAME COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) 2020-06-25 WO claimed
EP-3526274-A1 CATALYST SYSTEM EPC Engineering & Technologies GmbH (DE) 2019-08-21 EP claimed
US-8901302-B2 Pyrazino[2,3-D]isoxazole derivative which is useful as a production intermediate of pyrazine carboxamide derivative FUJIFILM CORPORATION (JP) 2014-12-02 US claimed
EP-2658026-A1 Fluoride ion battery compositions Contour Energy Systems, Inc. (US) 2013-10-30 EP claimed
US-8304580-B2 Method for producing tris(perfluoroalkanesulfonyl)methide acid salt CENTRAL GLASS COMPANY, LIMITED (JP) 2012-11-06 US claimed
US-20120164541-A1 FLUORIDE ION BATTERY COMPOSITIONS Contour Energy Systems, Inc. (US) 2012-06-28 US claimed
WO-2012087414-A2 FLUORIDE ION BATTERY COMPOSITIONS Contour Energy Systems, Inc. (US) 2012-06-28 WO claimed
EP-2080753-B1 METHOD FOR PRODUCING TRIS(PERFLUOROALKANESULFONYL)METHIDE ACID SALT CENTRAL GLASS CO LTD (JP) 2012-02-15 EP claimed
US-20110143219-A1 Fluoride Ion Battery Electrolyte Compositions Contour Energy Systems, Inc. (US) 2011-06-16 US claimed
US-20100022803-A1 Method for Producing Tris(Perfluoroalkanesulfonyl)Methide Acid Salt CENTRAL GLASS COMPANY, LIMITED (JP) 2010-01-28 US claimed
EP-2080753-A1 METHOD FOR PRODUCING TRIS(PERFLUOROALKANESULFONYL)METHIDE ACID SALT Central Glass Company, Limited (JP) 2009-07-22 EP claimed
US-4449005-A REACTING A CHLOROETHYL SULFIDE AND QUATERNARY AMMONIUM OR QUATERNARY PHOSPHONIUM FLUORIDE TO PRODUCE A VINYL SULFIDE THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) 1984-05-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022803-A1 Method for Producing Tris(Perfluoroalkanesulfonyl)Methide Acid Salt PFAS, AFF1, AFF2 HIF1A 3540/4885ALDH1A1 4582/4885MAPT 2278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.